What is Eli Lilly's market cap?

Eli Lilly (LLY) has a market capitalization of $1.10T and trades on NYSE.

What is Eli Lilly's revenue and profitability?

Eli Lilly generated $72.2B in trailing twelve-month revenue with net income of $25.3B, representing a net margin of 35.0%. Gross margin stands at 82.8%, with free cash flow of $11.8B. These figures are based on the Q1 2026 filing.

Who are Eli Lilly's competitors?

Eli Lilly's key competitors include Novo Nordisk, Pfizer Inc., Amgen Inc., and others. These companies compete in similar markets and product categories.

Who does Eli Lilly partner with?

Eli Lilly's notable partners include Boehringer Ingelheim, Incyte Corporation, Innovent Biologics, Inc., and others.

Where is Eli Lilly headquartered?

Eli Lilly is headquartered in United States of America and employs approximately 43,000 people. It has been publicly traded since 1970.

Eli Lilly

LLY

Eli Lilly and Company is a global pharmaceutical leader focused on the discovery, development, manufacturing, and marketing of innovative human medicines.

Market cap

$1.1T+57.2%

Revenue$72.2B+47.4%

Net income$25.3B+128%

Free cash flow$11.8B+216%

EPS (diluted)$28.15+129%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$19.8BBeat by $2.0B EPS$8.55Beat by $1.58

Read the full report

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$20.5B

EPS estimate$8.80

Financials

Q1 2026

Income statement

See full

Revenue$19.8B+55.5%

Gross profit$16.2B+54.4%

Net income$7.4B+168%

EPS (diluted)$8.26+170%

Balance sheet

See full

Cash & equivalents$5.3B+70.8%

Total debt$43.4B+12.6%

Total equity$31.2B+97.9%

Total assets$116.58B+30.4%

Cash flow

See full

Operating cash flow$5.3B+220%

CapEx$2.3B+54.0%

Free cash flow$3.0B+1,828%

Valuation & ratios

Valuation

See full

Market cap$1.1T+57.2%

Enterprise value$1.14T+54.9%

P/E43.6×-7.1×

P/S15.3×+2.1×

Profitability

See full

Gross margin82.8%+1.1pp

Net margin35%+12.3pp

FCF margin16.4%+8.7pp

Returns & leverage

See full

Return on equity107.6%+29.9pp

Debt / equity1.4×-1.1×

Current ratio1.5×+0.1×

Segments

By product

See full

Mounjaro$8.7B+125%

Zepbound$4.2B+79.9%

Verzenio$1.3B+12.3%

Jardiance$1.1B+9.9%

Other oncology$966.0M+22.4%

By geography

See full

Outside U.S.$7.7B—

Europe$3.6B+52.6%

Rest of world$2.8B+178%

By segment

See full

Reportable Segment$19.8B+55.5%

Competitors

By market cap

Eli Lilly$1.10T+57.5%

Johnson & Johnson$643.30B+71.9%

Cardinal Health$56.1B+45.2%

Lexicon Pharmaceuticals$1.1B+216%

By revenue growth

Lexicon Pharmaceuticals+123%

Eli Lilly+47.4%

Cardinal Health+12.8%

McKesson+12.4%

Amgen+9.1%

Johnson & Johnson+7.9%

Cencora+5.9%

Pfizer+1.4%

By net margin

Eli Lilly34.99%+12.3pp

Johnson & Johnson21.83%-2.6pp

Amgen20.96%+3.6pp

Pfizer15.65%+6.3pp

McKesson1.18%+0.3pp

Cardinal Health0.62%-0.1pp

Cencora0.599%+0.6pp

Lexicon Pharmaceuticals-37.46%+531pp

Profile

Eli Lilly and Company is a global pharmaceutical leader focused on the discovery, development, manufacturing, and marketing of innovative human medicines. The company specializes in high-growth therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience. Its core value proposition centers on delivering differentiated treatments that improve patient outcomes and provide value to global healthcare payers.

Competitive position

A leading global innovator in the pharmaceutical industry with a dominant position in the diabetes and anti-obesity markets.

GeographiesUnited States, Europe, Asia, China

Customer segmentsHealthcare providers, Wholesale distributors, Government health agencies, Patients

Business modelR&D-driven manufacturing, Direct-to-patient digital health, B2B wholesale distribution

SuppliersRaw material suppliers, Contract research organizations, Third-party manufacturing partners, Academic research institutions

CustomersMcKesson Corporation, Cencora, Inc., Cardinal Health, Inc., Pharmacy Benefit Managers, Hospitals, Retail Pharmacies

CountryUnited States of America

Listed1970

Employees43.0K

CEODavid A. Ricks

SectorHealthcare

IndustryDrug Manufacturers - General

Websitelilly.com

FilingsSEC EDGAR

Ask your AI about Eli Lilly.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eli Lilly's market cap?: Eli Lilly (LLY) has a market capitalization of $1.10T and trades on NYSE.
What is Eli Lilly's revenue and profitability?: Eli Lilly generated $72.2B in trailing twelve-month revenue with net income of $25.3B, representing a net margin of 35.0%. Gross margin stands at 82.8%, with free cash flow of $11.8B. These figures are based on the Q1 2026 filing.
Who are Eli Lilly's competitors?: Eli Lilly's key competitors include Novo Nordisk, Pfizer Inc., Amgen Inc., and others. These companies compete in similar markets and product categories.
Who does Eli Lilly partner with?: Eli Lilly's notable partners include Boehringer Ingelheim, Incyte Corporation, Innovent Biologics, Inc., and others.
Where is Eli Lilly headquartered?: Eli Lilly is headquartered in United States of America and employs approximately 43,000 people. It has been publicly traded since 1970.